Temat: "Pyrimidines" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Design, synthesis, and biological evaluation of 2,4-diamino pyrimidine derivatives as potent FAK inhibitors with anti-cancer and anti-angiogenesis activities.
Autorzy :: Wang S; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhang RH; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Zhang H; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Wang YC; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yang D; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhao YL; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Yan GY; Department of Hepatobiliary Pancreatic Surgery, Henan Provincial People's Hospital, Henan University, Zhengzhou, PR China.
Xu GB; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Guan HY; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Zhou YH; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Cui DB; Center for Tissue Engineering and Stem Cell Research, Key Laboratory of Regenerative Medicine of Guizhou Province, Guizhou Medical University, Guiyang, 550004, PR China.
Liu T; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Li YJ; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China.
Liao SG; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .
Zhou M; State Key Laboratory of Functions and Applications of Medicinal Plants, Engineering Research Center for the Development and Application of Ethnic Medicine and TCM (Ministry of Education), Guizhou Medical University, Guiyang, 550004, PR China; School of Pharmacy, Guizhou Medical University, Guian New District, Guizhou, PR China. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113573. Date of Electronic Publication: 2021 May 29.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Design*
Angiogenesis Inhibitors/*pharmacology
Antineoplastic Agents/*pharmacology
Focal Adhesion Kinase 1/*antagonists & inhibitors
Neovascularization, Pathologic/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Angiogenesis Inhibitors/chemical synthesis ; Angiogenesis Inhibitors/chemistry ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Cells, Cultured ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Focal Adhesion Kinase 1/metabolism ; Humans ; Molecular Structure ; Neovascularization, Pathologic/metabolism ; Neovascularization, Pathologic/pathology ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
Autorzy :: Jiang B; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Jiang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Kaltheuner IH; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Iniguez AB; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Anand K; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Ferguson FM; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Ficarro SB; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Seong BKA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Greifenberg AK; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Dust S; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Kwiatkowski NP; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Blais Proteomics Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; The Broad Institute, Cambridge, MA, 02142, USA.
Zhang T; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.
Geyer M; Institute of Structural Biology, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113481. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Discovery*
Anilides/*pharmacology
CDC2 Protein Kinase/*antagonists & inhibitors
Cyclin-Dependent Kinases/*antagonists & inhibitors
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Anilides/chemical synthesis ; Anilides/chemistry ; Animals ; CDC2 Protein Kinase/metabolism ; Cells, Cultured ; Cyclin-Dependent Kinases/metabolism ; Dose-Response Relationship, Drug ; Humans ; Male ; Mice ; Microsomes, Liver/chemistry ; Microsomes, Liver/metabolism ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: 1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.
Autorzy :: Pismataro MC; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Felicetti T; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Bertagnin C; Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121, Padua, Italy.
Nizi MG; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Bonomini A; Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121, Padua, Italy.
Barreca ML; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Cecchetti V; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Jochmans D; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Box 1043, 3000, Leuven, Belgium.
De Jonghe S; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Box 1043, 3000, Leuven, Belgium.
Neyts J; KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Herestraat 49, Box 1043, 3000, Leuven, Belgium.
Loregian A; Department of Molecular Medicine, University of Padua, Via Gabelli 63, 35121, Padua, Italy.
Tabarrini O; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy.
Massari S; Department of Pharmaceutical Sciences, University of Perugia, Via Del Liceo 1, 06123, Perugia, Italy. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113494. Date of Electronic Publication: 2021 Apr 26.
Typ publikacji :: Journal Article
MeSH Terms :: Antiviral Agents/*pharmacology
Protein Multimerization/*drug effects
Pyrimidines/*pharmacology
RNA-Dependent RNA Polymerase/*antagonists & inhibitors
Triazoles/*pharmacology
Viral Proteins/*antagonists & inhibitors
Animals ; Antiviral Agents/chemical synthesis ; Chlorocebus aethiops ; Dogs ; Drug Design ; HEK293 Cells ; Humans ; Influenza A virus/drug effects ; Madin Darby Canine Kidney Cells ; Microbial Sensitivity Tests ; Pyrimidines/chemical synthesis ; SARS-CoV-2/drug effects ; Triazoles/chemical synthesis ; Vero Cells
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy.
Autorzy :: Ayati A; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Moghimi S; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Toolabi M; Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran; Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Electronic address: .
Foroumadi A; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 05; Vol. 221, pp. 113523. Date of Electronic Publication: 2021 May 04.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Antineoplastic Agents/*pharmacology
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/metabolism ; Humans ; Molecular Structure ; Neoplasms/metabolism ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Autorzy :: Javle M; Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Roychowdhury S; James Cancer Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA; Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Kelley RK; Department of Medicine, Division of Hematology/Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Sadeghi S; Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Macarulla T; Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
Weiss KH; Internal Medicine, Salem Medical Center, Heidelberg, Germany; Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany.
Waldschmidt DT; Clinic for Gastroenterologie and Hepatologie, Klinikum der Universität zu Köln, Cologne, Germany.
Goyal L; Hematology/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Borbath I; Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium.
El-Khoueiry A; Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.
Borad MJ; Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Yong WP; National University Cancer Institute Singapore, National University Health System, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Philip PA; Karmanos Cancer Institute, Detroit, MI, USA.
Bitzer M; Department of Internal Medicine I, Eberhard-Karls University, Tübingen, Germany; Center for Personalized Medicine, Eberhard-Karls University, Tübingen, Germany.
Tanasanvimon S; Internal Medicine, Chulalongkorn University, Bangkok, Thailand.
Li A; Biostatistics and Data Management, QED Therapeutics, San Francisco, CA, USA.
Pande A; Clinical Development, QED Therapeutics, San Francisco, CA, USA.
Soifer HS; Translational Medicine, QED Therapeutics, San Francisco, CA, USA.
Shepherd SP; Clinical Development, QED Therapeutics, San Francisco, CA, USA.
Moran S; Clinical Development, QED Therapeutics, San Francisco, CA, USA.
Zhu AX; Medicine, Massachusetts General Hospital Cancer Center, Boston, MA, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China.
Bekaii-Saab TS; Department of Medical Oncology and Hematology, Mayo Clinic, Scottsdale, AZ, USA.
Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.; Pokaż więcej
Źródło :: The lancet. Gastroenterology & hepatology [Lancet Gastroenterol Hepatol] 2021 Oct; Vol. 6 (10), pp. 803-815. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :: Cholangiocarcinoma/*drug therapy
Cholangiocarcinoma/*genetics
Neoplasm Metastasis/*drug therapy
Phenylurea Compounds/*therapeutic use
Pyrimidines/*therapeutic use
Receptor, Fibroblast Growth Factor, Type 1/*antagonists & inhibitors
Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Alopecia/chemically induced ; Alopecia/epidemiology ; Central Serous Chorioretinopathy/chemically induced ; Central Serous Chorioretinopathy/epidemiology ; Cholangiocarcinoma/secondary ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Disease Progression ; Dry Eye Syndromes/chemically induced ; Dry Eye Syndromes/epidemiology ; Fatigue/chemically induced ; Fatigue/epidemiology ; Female ; Humans ; Hyperphosphatemia/chemically induced ; Hyperphosphatemia/epidemiology ; Male ; Middle Aged ; Neoplasm Metastasis/pathology ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Radiation-Sensitizing Agents/administration & dosage ; Radiation-Sensitizing Agents/therapeutic use ; Receptor, Fibroblast Growth Factor, Type 2/genetics ; Retinal Detachment/chemically induced ; Retinal Detachment/epidemiology ; Safety ; Stomatitis/chemically induced ; Stomatitis/epidemiology ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Autorzy :: Erman M; Medical Oncology, Hacettepe University, Ankara, Turkey.
Biswas B; Medical Oncology, Tata Medical Center, Kolkata, West Bengal, India.
Danchaivijitr P; Medical Oncology, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Chen L; Medical Oncology, The First Affiliated Hospital of Sun Yat-sen, Guangzhou, Guangdong Province, China.
Wong YF; Radiotherapy and Oncology, National Cancer Institute, Putrajaya, Malaysia.
Hashem T; Medical Oncology, Dr Tarek Hashem's Clinic, Cairo, Egypt.
Lim CS; Clinical Oncology, Sultan Ismail Hospital, Johor Bahru, Malaysia.
Karabulut B; Medical Oncology, Ege University, Izmir, Turkey.
Chung HJ; Department of Urology, Taipei Veterans General Hospital and Department of Urology, College of Medicine and Shu-Tien Urological Research Cente, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Chikatapu C; Oncology, Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India.
Ingles S; Oncology, Novartis Pharma AG, Basel, Switzerland.
Slimane K; Oncology, Novartis Pharma SAS, Rueil-Malmaison, France.
Kanesvaran R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. .; Pokaż więcej
Źródło :: BMC cancer [BMC Cancer] 2021 Sep 14; Vol. 21 (1), pp. 1021. Date of Electronic Publication: 2021 Sep 14.
Typ publikacji :: Clinical Trial, Phase IV; Journal Article; Observational Study
MeSH Terms :: Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Indazoles/*therapeutic use
Kidney Neoplasms/*drug therapy
Pyrimidines/*therapeutic use
Sulfonamides/*therapeutic use
Adult ; Africa, Northern ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Asia ; Carcinoma, Renal Cell/ethnology ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Female ; Humans ; Indazoles/administration & dosage ; Indazoles/adverse effects ; Kidney Neoplasms/ethnology ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Middle East ; Progression-Free Survival ; Prospective Studies ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Response Evaluation Criteria in Solid Tumors ; Risk Factors ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Time Factors ; Treatment Outcome ; Young Adult
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
Autorzy :: Dababou S; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Garzon S; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Laganà AS; Department of Obstetrics and Gynecology, 'Filippo Del Ponte' Hospital, University of Insubria, Varese (VA), Italy.
Ferrero S; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genova, Italy.; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Evangelisti G; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genova, Italy.; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Noventa M; Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padua, Padua, Italy.
D'Alterio MN; Department of Surgical Sciences, Section of Obstetrics & Gynecology, University of Cagliari, Monserrato, Italy.
Palomba S; Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy.
Uccella S; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Franchi M; Department of Obstetrics and Gynecology, AOUI Verona, University of Verona, Verona, Italy.
Barra F; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (Dinogmi), University of Genova, Italy.; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.; Pokaż więcej
Źródło :: Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2021 Sep; Vol. 30 (9), pp. 903-911. Date of Electronic Publication: 2021 Aug 04.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Carboxylic Acids/*administration & dosage
Endometriosis/*drug therapy
Leiomyoma/*drug therapy
Pyrimidines/*administration & dosage
Uterine Neoplasms/*drug therapy
Carboxylic Acids/adverse effects ; Carboxylic Acids/pharmacology ; Dose-Response Relationship, Drug ; Female ; Gonadotropin-Releasing Hormone/antagonists & inhibitors ; Hormone Antagonists/administration & dosage ; Hormone Antagonists/adverse effects ; Hormone Antagonists/pharmacology ; Humans ; Pyrimidines/adverse effects ; Pyrimidines/pharmacology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Recognition of single-stranded nucleic acids by small-molecule splicing modulators.
Autorzy :: Tang Z; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Akhter S; Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047, USA.
Ramprasad A; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Wang X; Analytical Research & Development, Merck and Co., Inc., Kenilworth, NJ 07033, USA.
Reibarkh M; Analytical Research & Development, Merck and Co., Inc., Kenilworth, NJ 07033, USA.
Wang J; Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047, USA.
Aryal S; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Thota SS; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Zhao J; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.
Douglas JT; Nuclear Magnetic Resonance Lab, University of Kansas, Lawrence, KS 66045, USA.
Gao P; Protein Production Group, University of Kansas, Lawrence, KS 66047, USA.
Holmstrom ED; Department of Molecular Biosciences and Department of Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Miao Y; Center for Computational Biology and Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66047, USA.
Wang J; Department of Medicinal Chemistry, University of Kansas, Lawrence, KS 66047, USA.; Pokaż więcej
Źródło :: Nucleic acids research [Nucleic Acids Res] 2021 Aug 20; Vol. 49 (14), pp. 7870-7883.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: RNA Splicing*
Azo Compounds/*metabolism
Muscular Atrophy, Spinal/*genetics
Pyrimidines/*metabolism
RNA Precursors/*genetics
Azo Compounds/chemistry ; Azo Compounds/therapeutic use ; Base Sequence ; Binding Sites/genetics ; DNA, Single-Stranded/chemistry ; DNA, Single-Stranded/genetics ; DNA, Single-Stranded/metabolism ; Exons/genetics ; Kinetics ; Magnetic Resonance Spectroscopy/methods ; Molecular Dynamics Simulation ; Molecular Structure ; Muscular Atrophy, Spinal/drug therapy ; Muscular Atrophy, Spinal/metabolism ; Mutation ; Neuromuscular Agents/chemistry ; Neuromuscular Agents/metabolism ; Neuromuscular Agents/therapeutic use ; Nucleic Acid Conformation ; Pyrimidines/chemistry ; Pyrimidines/therapeutic use ; RNA Precursors/chemistry ; RNA Precursors/metabolism ; Survival of Motor Neuron 2 Protein/genetics
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Autorzy :: Xu D; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Sun D; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; School of Life Science and Technology, Shanghai Tech University, 393 Middle Huaxia Road, Pudong New District, Shanghai, 201210, China.
Wang W; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China.
Peng X; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Zhan Z; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Ji Y; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Shen Y; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China.
Geng M; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; School of Life Science and Technology, Shanghai Tech University, 393 Middle Huaxia Road, Pudong New District, Shanghai, 201210, China.
Ai J; Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China; Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Xiangshan Branch Lane, Xihu District, Hangzhou, 330106, China. Electronic address: .
Duan W; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), 555 Zu Chong Zhi Road, Shanghai, 201203, China; University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing, 100049, China. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Aug 05; Vol. 220, pp. 113497. Date of Electronic Publication: 2021 Apr 25.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Discovery*
Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins/*antagonists & inhibitors
Pyrimidines/*pharmacology
Pyrroles/*pharmacology
Receptor Protein-Tyrosine Kinases/*antagonists & inhibitors
Animals ; Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Male ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Proto-Oncogene Proteins/metabolism ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Pyrroles/chemical synthesis ; Pyrroles/chemistry ; Rats ; Rats, Sprague-Dawley ; Receptor Protein-Tyrosine Kinases/metabolism ; Structure-Activity Relationship ; Tumor Cells, Cultured
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Discovery and mechanism of action studies of 4,6-diphenylpyrimidine-2-carbohydrazides as utrophin modulators for the treatment of Duchenne muscular dystrophy.
Autorzy :: Vuorinen A; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Wilkinson IVL; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Chatzopoulou M; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Edwards B; Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, UK.
Squire SE; Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, UK.
Fairclough RJ; Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, UK.
Bazan NA; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Milner JA; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Conole D; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Donald JR; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Shah N; Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, UK.
Willis NJ; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Martínez RF; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Wilson FX; Summit Therapeutics Plc, 136a Eastern Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4SB, UK.
Wynne GM; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Davies SG; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK.
Davies KE; Department of Physiology, Anatomy and Genetics, University of Oxford, Sir Henry Wellcome Building of Gene Function, South Parks Road, Oxford, OX1 3PT, UK. Electronic address: .
Russell AJ; Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK; Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3PQ, UK. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Aug 05; Vol. 220, pp. 113431. Date of Electronic Publication: 2021 Apr 20.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Discovery*
Hydrazines/*pharmacology
Muscular Dystrophy, Duchenne/*drug therapy
Pyrimidines/*pharmacology
Utrophin/*metabolism
Dose-Response Relationship, Drug ; Humans ; Hydrazines/chemical synthesis ; Hydrazines/chemistry ; Molecular Structure ; Muscular Dystrophy, Duchenne/metabolism ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; RNA, Messenger/metabolism ; Structure-Activity Relationship
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Discovery of highly potent tubulin polymerization inhibitors: Design, synthesis, and structure-activity relationships of novel 2,7-diaryl-[1,2,4]triazolo[1,5-a]pyrimidines.
Autorzy :: Huo XS; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Jian XE; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Ou-Yang J; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Chen L; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Yang F; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Lv DX; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
You WW; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China.
Rao JJ; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China. Electronic address: .
Zhao PL; Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, 510515, PR China. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Aug 05; Vol. 220, pp. 113449. Date of Electronic Publication: 2021 Apr 16.
Typ publikacji :: Journal Article
MeSH Terms :: Drug Discovery*
Antineoplastic Agents/*pharmacology
Pyrimidines/*pharmacology
Tubulin/*metabolism
Tubulin Modulators/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Cell Line ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Polymerization/drug effects ; Pyrimidines/chemical synthesis ; Pyrimidines/chemistry ; Structure-Activity Relationship ; Tubulin Modulators/chemical synthesis ; Tubulin Modulators/chemistry
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Synthesis and Neurotropic Activity of New Heterocyclic Systems: Pyridofuro[3,2- d ]pyrrolo[1,2- a ]pyrimidines, Pyridofuro[3,2- d ]pyrido[1,2- a ]pyrimidines and Pyridofuro[3',2':4,5]pyrimido[1,2- a ]azepines.
Autorzy :: Sirakanyan SN; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.
Spinelli D; Dipartimento di Chimica G. Ciamician, Alma Mater Studiorum-Università di Bologna, Via F. Selmi 2, 40126 Bologna, Italy.
Geronikaki A; School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Kartsev V; InterBioScreen, a/ya 218, 119019 Moscow, Russia.
Hakobyan EK; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.
Petrou A; School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Paronikyan RG; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.
Nazaryan IM; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.
Akopyan HH; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.
Hovakimyan AA; Scientific Technological Center of Organic and Pharmaceutical Chemistry of National Academy of Science of Republic of Armenia, Institute of Fine Organic Chemistry of A.L. Mnjoyan, Ave. Azatutyan 26, Yerevan 0014, Armenia.; Pokaż więcej
Źródło :: Molecules (Basel, Switzerland) [Molecules] 2021 Jun 01; Vol. 26 (11). Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :: Journal Article
MeSH Terms :: Azepines/*administration & dosage
Azepines/*chemical synthesis
Pyrimidines/*administration & dosage
Pyrimidines/*chemical synthesis
Seizures/*drug therapy
Animals ; Anti-Anxiety Agents/administration & dosage ; Anti-Anxiety Agents/chemical synthesis ; Anti-Anxiety Agents/chemistry ; Anti-Anxiety Agents/pharmacology ; Anticonvulsants/administration & dosage ; Anticonvulsants/chemical synthesis ; Anticonvulsants/chemistry ; Anticonvulsants/pharmacology ; Azepines/chemistry ; Azepines/pharmacology ; Disease Models, Animal ; Male ; Maze Learning/drug effects ; Models, Molecular ; Molecular Docking Simulation ; Molecular Structure ; Pentylenetetrazole/adverse effects ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; RNA-Binding Proteins/chemistry ; RNA-Binding Proteins/metabolism ; Rats ; Receptors, GABA-A/chemistry ; Receptors, GABA-A/metabolism ; Seizures/chemically induced ; Seizures/physiopathology
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 13 13.

Tytuł :: Metal binding 6-arylthio-3-hydroxypyrimidine-2,4-diones inhibited human cytomegalovirus by targeting the pUL89 endonuclease of the terminase complex.
Autorzy :: Wang L; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA; Department of Pharmaceutical Science, School of Chemical Engineering, Dalian University of Technology, 116024, Dalian, China.
Edwards TC; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Sahani RL; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Xie J; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Aihara H; Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN, 55455, USA.
Geraghty RJ; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Wang Z; Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Oct 15; Vol. 222, pp. 113640. Date of Electronic Publication: 2021 Jun 12.
Typ publikacji :: Journal Article
MeSH Terms :: Antiviral Agents/*pharmacology
Coordination Complexes/*pharmacology
Cytomegalovirus/*drug effects
Endonucleases/*antagonists & inhibitors
Enzyme Inhibitors/*pharmacology
Pyrimidines/*pharmacology
Antiviral Agents/chemical synthesis ; Antiviral Agents/chemistry ; Cell Line ; Cell Survival/drug effects ; Coordination Complexes/chemical synthesis ; Coordination Complexes/chemistry ; Cytomegalovirus/enzymology ; Dose-Response Relationship, Drug ; Endonucleases/metabolism ; Enzyme Inhibitors/chemical synthesis ; Enzyme Inhibitors/chemistry ; Humans ; Models, Molecular ; Molecular Structure ; Pyrimidines/chemistry ; Structure-Activity Relationship ; Virus Replication/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Pharmacokinetics and metabolic disposition of a potent and selective kynurenine monooxygenase inhibitor, CHDI-340246, in laboratory animals.
Autorzy :: Khetarpal V; CHDI Management/CHDI Foundation, Princeton, NJ, USA.
Herbst T; CHDI Management/CHDI Foundation, Princeton, NJ, USA.
Shefchek D; Covance Laboratories Inc, Madison, WI, USA.
Ash S; Covance Laboratories Inc, Madison, WI, USA.
Fitzsimmons M; Covance Laboratories Inc, Madison, WI, USA.
Gohdes M; Covance Laboratories Inc, Madison, WI, USA.
Munoz-Sanjuan I; CHDI Management/CHDI Foundation, Princeton, NJ, USA.
Dominguez C; CHDI Management/CHDI Foundation, Princeton, NJ, USA.; Pokaż więcej
Źródło :: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2021 Oct; Vol. 51 (10), pp. 1155-1180. Date of Electronic Publication: 2021 Sep 15.
Typ publikacji :: Journal Article
MeSH Terms :: Kynurenine*
Pyrimidines*
Animals ; Animals, Laboratory ; Dogs ; Mice ; Mixed Function Oxygenases ; Rats ; Species Specificity
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States.
Autorzy :: Poulos C; Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA.
Soliman AM; Health Economics and Outcomes Research (HEOR), AbbVie Inc, North Chicago, IL, USA.
Tekin S; Health Economics and Outcomes Research (HEOR), AbbVie Inc, North Chicago, IL, USA.
Agarwal SK; Center for Endometriosis Research and Treatment, University of California San Diego, La Jolla, CA, USA.; Pokaż więcej
Źródło :: Expert review of pharmacoeconomics & outcomes research [Expert Rev Pharmacoecon Outcomes Res] 2021 Oct; Vol. 21 (5), pp. 1091-1099. Date of Electronic Publication: 2020 Nov 03.
Typ publikacji :: Comparative Study; Journal Article
MeSH Terms :: Endometriosis/*drug therapy
Hydrocarbons, Fluorinated/*administration & dosage
Leuprolide/*administration & dosage
Pain/*drug therapy
Pyrimidines/*administration & dosage
Adolescent ; Adult ; Choice Behavior ; Endometriosis/complications ; Female ; Humans ; Hydrocarbons, Fluorinated/adverse effects ; Leuprolide/adverse effects ; Middle Aged ; Pain/etiology ; Patient Preference ; Pregnancy ; Pregnancy Complications/etiology ; Pyrimidines/adverse effects ; Severity of Illness Index ; Surveys and Questionnaires ; United States ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Autorzy :: Dómine Gómez M; Medical Oncology Department, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain.
Csőszi T; County Oncology Centre, Hetenyi Geza Korhaz, Szolnok, Hungary.
Jaal J; Institute of Clinical Medicine, Department of Hematology and Oncology, University of Tartu, Tartu, Estonia.
Kudaba I; Chemotherapy and Haematology Clinic, Riga East Clinical University-Latvian Oncology Center, Riga, Latvia.
Nikolov K; Department of Medical Oncology, Complex Oncology Center, Burgas, Bulgaria.
Radosavljevic D; Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Xiao J; Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.
Horton JK; Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.
Malik RK; Clinical Development, G1 Therapeutics, Inc., Research Triangle Park, North Carolina, USA.
Subramanian J; Division of Oncology, Saint Luke's Cancer Institute, University of Missouri, Kansas City, Missouri, USA.; Pokaż więcej
Źródło :: International journal of cancer [Int J Cancer] 2021 Oct 01; Vol. 149 (7), pp. 1463-1472. Date of Electronic Publication: 2021 Jul 10.
Typ publikacji :: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Cytoprotection*
Hematologic Diseases/*prevention & control
Lung Neoplasms/*drug therapy
Myeloid Cells/*drug effects
Pyrimidines/*administration & dosage
Pyrroles/*administration & dosage
Small Cell Lung Carcinoma/*drug therapy
Aged ; Double-Blind Method ; Female ; Follow-Up Studies ; Hematologic Diseases/chemically induced ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Pyrimidines/adverse effects ; Pyrroles/adverse effects ; Small Cell Lung Carcinoma/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis.
Autorzy :: Seyedmousavi S; Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.; Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Chang YC; Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Youn JH; Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
Law D; F2G Ltd., Eccles, Cheshire, United Kingdom.
Birch M; F2G Ltd., Eccles, Cheshire, United Kingdom.
Rex JH; F2G Ltd., Eccles, Cheshire, United Kingdom.
Kwon-Chung KJ; Molecular Microbiology Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.; Pokaż więcej
Źródło :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Sep 17; Vol. 65 (10), pp. e0043421. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji :: Journal Article; Research Support, N.I.H., Intramural
MeSH Terms :: Pyrimidines*
Scedosporium*
Acetamides ; Animals ; Antifungal Agents/therapeutic use ; Invasive Fungal Infections ; Mice ; Piperazines ; Pyrroles
SCR Disease Name :: scedosporiosis
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: The GABA B receptor positive allosteric modulator ASP8062 reduces operant alcohol self-administration in male and female Sprague Dawley rats.
Autorzy :: Haile CN; Department of Psychology & TIMES, University of Houston, 4849 Calhoun Rd, Houston, TX, 77204-6022, USA. .
Carper BA; Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA.
Nolen TL; Biostatistics and Epidemiology Division, RTI International, Research Triangle Park, NC, USA.
Kosten TA; Department of Psychology & TIMES, University of Houston, 4849 Calhoun Rd, Houston, TX, 77204-6022, USA.; Pokaż więcej
Źródło :: Psychopharmacology [Psychopharmacology (Berl)] 2021 Sep; Vol. 238 (9), pp. 2587-2600. Date of Electronic Publication: 2021 Jul 06.
Typ publikacji :: Journal Article
MeSH Terms :: Pyrimidines*
Receptors, GABA-B*
Allosteric Regulation ; Animals ; Baclofen/pharmacology ; Conditioning, Operant ; Female ; GABA-B Receptor Agonists/pharmacology ; Male ; Morpholines ; Rats ; Rats, Sprague-Dawley ; Self Administration
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Autorzy :: Simpson EL; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Nosbaum A; Department of Allergy and Clinical Immunology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite, France.
Winthrop KL; Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
Guttman-Yassky E; Department of Dermatology and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Hoffmeister KM; Versiti, Translational Glycomics Center, Blood Research Institute, Milwaukee, WI, USA.; Departments of Biochemistry and Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Egeberg A; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.
Valdez H; Pfizer Inc., New York, NY, USA.
Zhang M; Pfizer Inc., La Jolla, CA, USA.
Farooqui SA; Pfizer R & D UK Ltd., Kent, UK.
Romero W; Pfizer Ltd., Surrey, UK.
Thorpe AJ; Pfizer Inc., Collegeville, PA, USA.
Rojo R; Pfizer Inc., Groton, CT, USA.
Johnson S; Pfizer Inc., Collegeville, PA, USA. .; Pokaż więcej
Źródło :: American journal of clinical dermatology [Am J Clin Dermatol] 2021 Sep; Vol. 22 (5), pp. 693-707. Date of Electronic Publication: 2021 Aug 18.
Typ publikacji :: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :: Dermatitis, Atopic/*drug therapy
Infections/*epidemiology
Protein Kinase Inhibitors/*adverse effects
Pyrimidines/*adverse effects
Skin Neoplasms/*epidemiology
Sulfonamides/*adverse effects
Acne Vulgaris/chemically induced ; Adolescent ; Adult ; Aged ; Cardiovascular Diseases/epidemiology ; Cholesterol, HDL/blood ; Cholesterol, LDL/blood ; Female ; Headache/chemically induced ; Herpes Simplex/epidemiology ; Herpes Zoster/epidemiology ; Humans ; Incidence ; Lymphocyte Count ; Male ; Middle Aged ; Nausea/chemically induced ; Platelet Count ; Protein Kinase Inhibitors/administration & dosage ; Pyrimidines/administration & dosage ; Risk Factors ; Sulfonamides/administration & dosage ; Time Factors ; Venous Thromboembolism/epidemiology ; Young Adult
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: 5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness?
Autorzy :: Tetangco EP; Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Hanauer SB; Pokaż więcej
Źródło :: The American journal of gastroenterology [Am J Gastroenterol] 2021 Sep 01; Vol. 116 (9), pp. 1958-1959.
Typ publikacji :: Letter; Comment
MeSH Terms :: Biological Products*
Pyrimidines*
Cost-Benefit Analysis ; Humans ; Piperidines ; Pyrroles
: Opinia redakcyjna

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Pyrimidines"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język